AbbVie’s Allergan Aesthetics Advances Personalized Treatment Plans in Evolving Aesthetic Medicine Market

### Shifting Paradigms in Aesthetic Medicine: AbbVie’s Allergan Aesthetics Sets New Standards

Allergan Aesthetics, a subsidiary of AbbVie, reveals significant findings from new global research that indicates a major evolution in consumer preferences within the aesthetic medicine industry. The study, which includes data from over 12,000 consumers across nine nations, points to a rising demand for customized multimodal treatment plans rather than singular approaches. A core aspect of this research highlights that 62% of consumers are drawn to multiple treatment options, while 59% endorse a structured, multi-treatment plan for enhanced results. This transition is grounded in the consumer desire for natural-looking outcomes, thereby shifting the focus toward holistic approaches in aesthetic treatments.

Mark Wilson, Senior Vice President of International at Allergan Aesthetics, emphasizes the necessity of aligning treatment paradigms with consumer expectations. The firm’s research underscores that 78% of respondents express stronger satisfaction with long-term treatment strategies crafted in collaboration with their practitioners. This deep understanding of consumer insights becomes foundational as Allergan Aesthetics prepares to unveil its AA Signature™ framework during the upcoming Aesthetic and Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco. The upgraded framework aims to provide healthcare professionals with guidance in crafting personalized aesthetic journeys that integrate Allergan’s extensive product offerings with complementary modalities.

The findings will culminate in the launch of a report titled "Layered Beauty: The New Aesthetic Mindset," set to be introduced at AMWC 2026. This report aims to further clarify the importance of structured treatment frameworks and ongoing education for enhancing patient experiences and outcomes in aesthetic medicine. By prioritizing natural-looking results through expert consultation, Allergan Aesthetics confirms its commitment to responsiveness in an industry increasingly defined by personalization and holistic care. As consumer needs evolve, Allergan Aesthetics positions itself as a leader in the aesthetic arena, paving the way for future innovations that align with patient preferences.

In a related development outside of aesthetic medicine, the U.S. Food and Drug Administration (FDA) recently approves Icotyde (icotrokinra) for treating moderate-to-severe plaque psoriasis. This new therapy represents a promising addition to the pharmaceutical landscape, specifically targeting the needs of patients with chronic inflammatory skin conditions.

Allergan Aesthetics’ focus on consumer-driven research and innovative frameworks operates within a broader context of improving healthcare outcomes, suggesting a transformative period in the industry as it shifts toward increasingly personalized medicine.